On September 6, 2023, NurExone Biologic Inc., closed the transaction. The company issued 750,000 units at a price of CAD 0.275 per unit for the gross proceeds of CAD 206,250 in the second and final tranche closing. The company has issued total 5,394,548 units at a price of CAD 0.275 per unit for aggregate proceeds of CAD 1,483,500.70 under the Private Placement.

The TSX Venture Exchange has accepted for filing documentation with respect to the transaction. The transaction included participation from 12 placees.
The company has received CAD 1,009,791.0596 ($742,166) from 6 investors pursuant to Regulation D.